Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Proceedings of the National Academy of Sciences of the United States of America
|
July 10, 2012
HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120
James M Kovacs, Joseph P Nkolola, Hanqin Peng, et al.
Vaccine
|
February 22, 2014
Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer
Joseph P Nkolola, Ann Cheung, James R Perry, et al.
Med (New York, N.Y.)
|
April 14, 2023
An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses
Eva Gutierrez, Mitchell Bigelow, Colin LaCroix, et al.
BMC Pediatrics
|
November 11, 2022
Utility of illness symptoms for predicting COVID-19 infections in children
Geena Y Zhou, Nicole Y Penwill, Grace Cheng, et al.
Nature Genetics
|
April 1, 2008
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
Kevin M Haigis, Krystle R Kendall, Yufang Wang, et al.
Journal of Virology
|
June 27, 2014
Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer
Joseph P Nkolola, Christine A Bricault, Ann Cheung, et al.
Journal of Virology
|
December 26, 2014
A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component
Christine A Bricault, James M Kovacs, Joseph P Nkolola, et al.
The Journal of Infectious Diseases
|
November 6, 2012
Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)
Dan H Barouch, Jinyan Liu, Lauren Peter, et al.
The Journal of Infectious Diseases
|
November 6, 2012
First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)
Lindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Proceedings of the National Academy of Sciences of the United States of America
|
July 10, 2012
HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120
James M Kovacs, Joseph P Nkolola, Hanqin Peng, et al.
Vaccine
|
February 22, 2014
Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer
Joseph P Nkolola, Ann Cheung, James R Perry, et al.
Med (New York, N.Y.)
|
April 14, 2023
An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses
Eva Gutierrez, Mitchell Bigelow, Colin LaCroix, et al.
BMC Pediatrics
|
November 11, 2022
Utility of illness symptoms for predicting COVID-19 infections in children
Geena Y Zhou, Nicole Y Penwill, Grace Cheng, et al.
Nature Genetics
|
April 1, 2008
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
Kevin M Haigis, Krystle R Kendall, Yufang Wang, et al.
Journal of Virology
|
June 27, 2014
Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer
Joseph P Nkolola, Christine A Bricault, Ann Cheung, et al.
Journal of Virology
|
December 26, 2014
A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component
Christine A Bricault, James M Kovacs, Joseph P Nkolola, et al.
The Journal of Infectious Diseases
|
November 6, 2012
Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)
Dan H Barouch, Jinyan Liu, Lauren Peter, et al.
The Journal of Infectious Diseases
|
November 6, 2012
First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)
Lindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
Page
of 2